NCT02845297View on ClinicalTrials.gov

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

April 30, 2022

Study Completion Date

December 31, 2022

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

pembrolizumab

Intravenous pembrolizumab

DRUG

Azacitadine

Intravenous or subcutaneous

Trial Locations (3)

27599

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

29425

Medical University of South Carolina Hollings Cancer Center, Charleston

21231-2410

Johns Hopkins Oncology Center, Baltimore

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02845297 - Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients | Biotech Hunter | Biotech Hunter